-
Product Insights
NewMotus GI Medical Technologies Ltd Pipeline Insight and Competitive Landscape, 2023
Empower your strategies with our Motus GI Medical Technologies Ltd Pipeline Insight and Competitive Landscape, 2023 report and make more profitable business decisions. Motus GI Medical Technologies Ltd (Motus GI) is a Israeli-based pharmaceutical company that offers other healthcare services. Motus GI is headquartered in Tirat Carmel, Israel. GlobalData's Medical Devices company profile report, “Motus GI Medical Technologies Ltd Pipeline Insight and Competitive Landscape, 2023" provides information about the company overview and analysis on their pipeline products. This company profile...
-
Product Insights
NewNet Present Value Model: Vaxart Inc’s Norovirus [strains Norwalk GI.1 + Sydney GII.4] (bivalent) vaccine
Empower your strategies with our Net Present Value Model: Vaxart Inc's Norovirus [strains Norwalk GI.1 + Sydney GII.4] (bivalent) vaccine report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IMM-6-415 in Gastric Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IMM-6-415 in Gastric Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. IMM-6-415 in Gastric Cancer Drug Details: IMM-6-415 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IMM-6-415 in Metastatic Melanoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IMM-6-415 in Metastatic Melanoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. IMM-6-415 in Metastatic Melanoma Drug Details: IMM-6-415 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IMM-6-415 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IMM-6-415 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. IMM-6-415 in Solid Tumor Drug Details: IMM-6-415 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – A-315 in Esophageal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - A-315 in Esophageal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. A-315 in Esophageal Cancer Drug Details: A-315 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – A-315 in Pancreatic Ductal Adenocarcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - A-315 in Pancreatic Ductal Adenocarcinoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. A-315 in Pancreatic Ductal Adenocarcinoma Drug Details: A-315 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – A-315 in Gastroesophageal (GE) Junction Carcinomas
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - A-315 in Gastroesophageal (GE) Junction Carcinomas report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. A-315 in Gastroesophageal (GE) Junction Carcinomas Drug Details: A-315...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – A-315 in Metastatic Biliary Tract Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - A-315 in Metastatic Biliary Tract Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. A-315 in Metastatic Biliary Tract Cancer Drug Details: A-315...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IMM-6-415 in Metastatic Pancreatic Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IMM-6-415 in Metastatic Pancreatic Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. IMM-6-415 in Metastatic Pancreatic Cancer Drug Details: IMM-6-415 is under...